Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push 
Gold Prices Slide as Treasury Yields Surge, Fed Minutes in Focus 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
European Stocks Edge Higher as Fed Rate Pause Bets Rise 
UK Wage Growth Holds at 3.5% as Unemployment Rises 
Trump Says Iran Talks Halted as Strait of Hormuz Dispute Fuels Oil Concerns 
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts 
Australian Consumer Sentiment Jumps 6% in August as Rate Outlook Improves 
NAB Q3 Cash Earnings Rise 2% as Lower Credit Charges Boost Profit 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Asian Chip Stocks Plunge as Bond Yields Fuel AI Valuation Fears 
Citadel Warns High Treasury Yields Pose Broader Market Risks 
Add as a preferred source on Google
KT Corp. has collaborated with US-based NeuroSigma Inc. to build a business model and technology for electronic medicine to treat neurological disorders, such as attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.
Under the partnership, KTS will support the development of the next version of NeuroSigma's external trigeminal nerve stimulation (eTNS®) system while producing and commercializing the device in South Korea.
NeuoSigma is credited for developing the first device cleared by the US Food and Drug Administration to treat pediatric ADHD--the Monarch external Trigeminal Nerve Stimulation system,
The telecom operator said NeuoSigma's pediatric ADHD electronic treatment has fewer side effects than other existing medication and is set to receive further clearance from the FDA on depression and epilepsy treatment using the technology.
